Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2006 | Original article

Hypoxia imaging-directed radiation treatment planning

Authors: J.G. Rajendran, K.R.G. Hendrickson, A.M. Spence, M. Muzi, K.A. Krohn, D.A. Mankoff

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2006

Abstract

Increasing evidence supports the role of the tumor microenvironment in modulating cancer behavior. Tissue hypoxia, an important and common condition affecting the tumor microenvironment, is well established as a resistance factor in radiotherapy. Increasing evidence points to the ability of hypoxia to induce the expression of gene products, which confer aggressive tumor behavior and promote broad resistance to therapy. These factors suggest that determining the presence or absence of tumor hypoxia is important in planning cancer therapy. Recent advances in PET hypoxia imaging, conformal radiotherapy, and imaging-directed radiotherapy treatment planning now make it possible to perform hypoxia-directed radiotherapy. We review the biological aspects of tumor hypoxia and PET imaging approaches for measuring tumor hypoxia, along with methods for conformal radiotherapy and image-guided treatment, all of which provide the underpinnings for hypoxia-directed therapy. As a case example, we review emerging data on PET imaging of hypoxia to direct radiotherapy.

Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:537–549

Kourkourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I.Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys 2000;48:545s–553s

Scandurro AB, Weldon CW, Figueroa YG, Alam J, Beckman BS. Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells. Int J Oncol 2001;19:129–135PubMed

Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, et al. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 2000;110:374–381PubMedCrossRef

Rajendran JG, Wilson D, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. F-18 FMISO and F-18 FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nuc Med Mol Imaging 2003;30:695–704CrossRef

Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525–4528PubMed

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464–468PubMedCrossRef

Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996;271:32253–32259PubMedCrossRef

Guillemin K, Krasnow MA. The hypoxic response: huffing and HIFing. Cell 1997;89:9–12PubMedCrossRef

10.

Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med 1996;37:502–506PubMed

11.

Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001;42:170–175PubMed

12.

Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [¹⁸F]fluoromisonidazole and [¹⁸F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245–2252PubMedCrossRef

13.

Hall EJ. Radiobiology for the radiologist. Lippincott Williams & Wilkins, Philadelphia, PA; 2000

14.

Marples B, Greco O, Joiner MC, Scott SD. Molecular approaches to chemo-radiotherapy. Eur J Cancer 2002;38:231–239PubMedCrossRef

15.

Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10–21PubMedCrossRef

16.

Fowler JF. Eighth annual Juan del Regato lecture. Chemical modifiers of radiosensitivity—theory and reality: a review. Int J Radiat Oncol Biol Phys 1985;11:665–674PubMed

17.

Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003;195:1–16PubMedCrossRef

18.

Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313–341PubMedCrossRef

19.

Rajendran JG, Meyer J, Schwartz DL, Kinahan PE, Cheng P, Hummel SM, et al. Imaging with F-18 FMISO-PET permits hypoxia directed radiotherapy dose escalation for head and neck cancer. J Nucl Med 2003;44:415, 127P

20.

Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171–1182PubMedCrossRef

21.

Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000;6:157–162PubMedCrossRef

22.

Lee DJ, Moini M, Giuliano J, Westra WH. Hypoxic sensitizer and cytotoxin for head and neck cancer. Ann Acad Med Singapore 1996;25:397–404PubMed

23.

Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535–542PubMed

24.

Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 2000;153:84–192PubMedCrossRef

25.

Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol 1991;42:2387–2395PubMedCrossRef

26.

Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229–237PubMedCrossRef

27.

Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. Radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989;30:343–350PubMed

28.

Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [¹⁸F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417–428PubMed

29.

Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn, KA. Hypoxia and glucose metabolism in malignant tumors: evaluation by [¹⁸F]fluoromisonidazole and [¹⁸F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245–2252PubMedCrossRef

30.

Liu RS, Chu LS, Yen SH, Chang CP, Chou KL, Wu LC, et al. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med 1996;23:1384–1387PubMedCrossRef

31.

Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB, Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with¹⁸F-fluorinated tracers and positron emission tomography—a study evaluating [¹⁸F]fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629–637PubMedCrossRef

32.

Yeh SH, Liu RS, Wu LC, Yang DJ, Yen SH, Chang CW, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996;23:1378–1383PubMedCrossRef

33.

Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 2003;510:285–292PubMed

34.

Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with¹⁸F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106–113PubMed

35.

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155–1160PubMed

36.

Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of Cu-64-ATSM in vitro and in vivo in a hypoxic model. J Nucl Med 1999;40:177–183PubMed

37.

Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321–329PubMedCrossRef

38.

O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using¹⁸F-fluoromisonidazole and⁶⁴Cu(II)-diacetyl-bis(N ⁴-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493–1502PubMed

39.

Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998;41:501–510PubMedCrossRef

40.

Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998;8:107–114PubMedCrossRef

41.

Dogan N, Leybovich LB, Sethi A, Emami B. Improvement of dose distributions in abutment regions of intensity modulated radiation therapy and electron fields. Med Phys 2002;29:38–44PubMedCrossRef

42.

Svensson H, Moller TR. Developments in radiotherapy. Acta Oncol 2003;42:430–442PubMedCrossRef

43.

Williams PC. IMRT: delivery techniques and quality assurance. Br J Radiol 2003;76:766–776PubMedCrossRef

44.

Webb S. The physical basis of IMRT and inverse planning. Br J Radiol 2003;76:678–689PubMedCrossRef

45.

Verhey LJ. Issues in optimization for planning of intensity-modulated radiation therapy. Semin Radiat Oncol 2002;12:210–218PubMedCrossRef

46.

Goffman TE, Glatstein E. Intensity-modulated radiation therapy. Radiat Res 2002;158:115–117PubMedCrossRef

47.

Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001;51: 880–914

48.

Garden AS, Morrison WH, Rosenthal DI, Chao KS, Ang KK. Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol 2004;14:103–109PubMedCrossRef

49.

Eisbruch A, Foote RL, O’Sullivan B, Beitler JJ, Vikram B. Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 2002;12:238–249PubMedCrossRef

50.

Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol 2003;48:N31–N35PubMedCrossRef

51.

Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int J Cancer 2000;90:92–103PubMedCrossRef

52.

Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551–560PubMedCrossRef

53.

Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005;43:153–167PubMedCrossRef

54.

Rajendran JG, Schwartz DS, O’Sullivan J, Peterson LM, Ng P, Scarnhorst J, et al. Tumor hypoxia imaging with [F-18]FMISO PET in head and neck cancer: value of pre-therapy FMISO uptake in predicting survival. Clin Cancer Res; 2006; in press

55.

Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005;43:169–187PubMedCrossRef

56.

Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with¹⁸F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253–260PubMed

57.

Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck 2005;27:478–487PubMedCrossRef

58.

Yap JT, Carney JP, Hall NC, Townsend DW. Image-guided cancer therapy using PET/CT. Cancer J 2004;10:221–233PubMedCrossRef

59.

Heron DE, Andrade RS, Flickinger J, Johnson J, Agarwala SS, Wu A, et al. Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. Int J Radiat Oncol Biol Phys 2004;60:1419–1424PubMed

60.

Esthappan J, Mutic S, Malyapa RS, Grigsby PW, Zoberi I, Dehdashti F, et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2004;58:1289–1297PubMed

61.

Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic [¹⁸F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 2005;50:2209–2224PubMedCrossRef

62.

Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M. Kinetic analysis of dynamic¹⁸F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005;5:152PubMedCrossRef

63.

Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005;181:483–499PubMedCrossRef

64.

Mehta VK, Poen JC, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 2001;24:155–159PubMedCrossRef

65.

Johnson CR, Schmidt-Ullrich RK, Wazer DE. Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer 1992;69:2749–2754PubMedCrossRef

66.

Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003;57:875–890PubMed

67.

Ahmed RS, Kim RY, Duan J, Meleth S, De Los Santos JF, Fiveash JB. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys 2004;60:505–512PubMed

68.

Allen N. Respiration and oxidative metabolism of brain tumors. In: Kirsch WM, Paoletti EG, Paoletti P, editors. The experimental biology of brain tumors. Springfield: Charles C. Thomas;, 1972. p 243–274

69.

Ito M, Lammertsma AA, Wise RJ, Bernardi S, Frackowiak RS, Heather JD, et al. Measurement of regional cerebral blood flow and oxygen utilisation in patients with cerebral tumours using¹⁵O and positron emission tomography: analytical techniques and preliminary results. Neuroradiology 1982;23:63–74PubMedCrossRef

70.

Lammertsma AA, Frackowiak RS. Positron emission tomography. Crit Rev Biomed Eng 1985;13:125–169PubMed

71.

Rhodes CG, Wise RJ, Gibbs JM, Frackowiak RS, Hatazawa J, Palmer AJ, et al. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 1983;14:614–626PubMedCrossRef

72.

Tyler JL, Diksic M, Villemure JG, Evans AC, Meyer E, Yamamoto YL, et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987;28:1123–1133PubMed

73.

Wise RJS, Thomas DGT, Lammertsma AA, Rhodes CG. PET scanning of human brain tumors. Prog Exp Tumor Res 1984;27:154–169PubMed

74.

Baron JC, Rougemont D, Soussaline F, Bustany P, Crouzel C, Bousser MG, et al. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study. J Cereb Blood Flow Metab 1984;4:140–149PubMed

75.

Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004;64:920–927PubMedCrossRef

76.

Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886–1892PubMedCrossRef

77.

Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Biol Phys 1994;29:427–431

78.

Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with¹⁸F-fluoromisonidazole and¹⁵O-H₂O. J Nucl Med 2004;45:1851–1859PubMed

79.

Liu Q. Constriction to hypoxia-reoxygenation in isolated mouse coronary arteries: role of endothelium and superoxide. J Appl Physiol 1999;87:1392–1396PubMed

80.

Scott AM, Ramdave S, Hannah A, Pathmaraj K, Tochon-Danguy H, Sachinidis J, et al. Correlation of hypoxic cell fraction with glucose metabolic rate in gliomas with¹⁸F-fluoromisonidazole (FMISO) and¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET). J Nucl Med 2001;42:abstract 250, 267P

81.

Valk P, Mathis C, Prados M, Gilbert J, Budinger T. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133–2137PubMed

82.

Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52:997–1007PubMedCrossRef

83.

Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 1999;43:79–88PubMed

84.

Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS. Combined modality approach to treatment of malignant gliomas—re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988;6:279–284PubMed

85.

Salazar OM, Rubin P, Feldstein ML, Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 1979;5:1733–1740PubMed

86.

Davis LW. Malignant glioma—a nemesis which requires clinical and basic investigation in radiation oncology. Int J Radiat Oncol Biol Phys 1989;16:1355–1365PubMed

87.

Green SB, Byar DP, Strike TA, Alexander E, Brooks WH, Burger PC, et al. Randomized comparisons of BCNU, streptozotocin, radiosensitizer, and fractionation of radiotherapy in the post-operative treatment of malignant glioma. Proc ASCO 1984;3:260

88.

Nelson DF, Schoenfeld D, Weinstein AS, Nelson JS, Wasserman T, Goodman RL, et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study. Int J Radiat Oncol Biol Phys 1983;9:1143–1151PubMed

89.

Griffin TW, Davis R, Laramore G, Hendrickson F, Rodrigues Antunez A, Hussey D, et al. Fast neutron radiation therapy for glioblastoma multiforme. Results of an RTOG study. Am J Clin Oncol 1983;6:661–667PubMedCrossRef

90.

Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998;41:989–995PubMed

91.

Douglas JG, Stelzer KJ, Mankoff DA, Tralins KS, Krohn KA, Muzi M, et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2006;64:886–891PubMed

92.

Suzuki M, Nakamatsu K, Kanamori S, Okumra M, Uchiyama T, Akai F, Nishimura Y. Feasibility study of the simultaneous integrated boost (SIB) method for malignant gliomas using intensity-modulated radiotherapy (IMRT). Jpn J Clin Oncol 2003;33:271–277PubMedCrossRef

93.

Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146–1154PubMed

94.

Solberg TD, Agazaryan N, Goss BW, Dahlbom M, Lee SP. A feasibility study of¹⁸F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy. J Neurosurg 2004;101(Suppl 3):381–389PubMed

Title: Hypoxia imaging-directed radiation treatment planning
Authors: J.G. Rajendran
K.R.G. Hendrickson
A.M. Spence
M. Muzi
K.A. Krohn
D.A. Mankoff
Publication date: 01-07-2006
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0135-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hypoxia imaging-directed radiation treatment planning

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2006

αvβ3-integrin imaging: a new approach to characterise angiogenesis?

Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas

Current standards for response evaluation by imaging techniques

Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy

Monitoring chemotherapy and radiotherapy of solid tumors

Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose?